PLX Protalix BioTherapeutics Inc

AMEX
$2.72

Protalix BioTherapeutics Inc (PLX) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.2% since its last earnings release on August 12, 2026.

Protalix BioTherapeutics Beat Consensus Estimates
Wednesday, August 12, 2026 · 6:50 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 6:50 AM ET
Earnings Whisper
-
vs ($0.02)
Rev est $12.41M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Protalix BioTherapeutics Inc

Protalix BioTherapeutics, Inc. is a biopharmaceutical company engaged in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.